Literature DB >> 8139601

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.

R Marconi1, D Lefebvre-Caparros, A M Bonnet, M Vidailhet, B Dubois, Y Agid.   

Abstract

The aim of this study was to provide further insight into the phenomenology and pathophysiology of monophasic and biphasic dyskinesias induced by levodopa in Parkinson's disease. For this purpose, the type, localization, severity, and timing of dyskinesias were evaluated in 15 parkinsonian patients in relation to motor disability after administration of levodopa using a video-electromyographic recording device. Foot-dystonia, myoclonus, and akathisia were observed in most patients. The dyskinesias started in the foot, usually on the side most affected by the disease, and spread in an "ascending wave" to the contralateral side, the trunk, and upper extremities. In a few patients, onset was axial, spreading almost instantaneously to all limbs. The dyskinesias were dystonic and ballistic at the start, and became increasingly choreic as they attained the upper limbs. Their intensity was maximal in the lower limbs, then progressively decreased, while increasing in upper limbs and head. The results indicate that there is no strict dichotomy between biphasic and monophasic dyskinesias. In other words, there is a "continuum" between the first dyskinesias and those observed during the period of maximal clinical improvement. These dyskinesias can also appear in reverse order, as if there were an "oscillator" determining a sequence of alternating patterns.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139601     DOI: 10.1002/mds.870090103

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  33 in total

1.  Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex.

Authors:  D Caparros-Lefebvre; S Blond; M P Feltin; P Pollak; A L Benabid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Mirror movements in Parkinson's disease: effect of dopaminergic drugs.

Authors:  A J Espay; F Morgante; C Gunraj; R Chen; A E Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

4.  "Silly walks" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias.

Authors:  Evžen Růžička; Kateřina Zárubová; John G Nutt; Bastiaan R Bloem
Journal:  Mov Disord       Date:  2011-04-14       Impact factor: 10.338

5.  Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

Authors:  Yunmin Ding; Jacqueline Restrepo; Lisa Won; Dong-Youn Hwang; Kwang-Soo Kim; Un Jung Kang
Journal:  Neurobiol Dis       Date:  2007-04-10       Impact factor: 5.996

6.  An ambulatory dyskinesia monitor.

Authors:  A J Manson; P Brown; J D O'Sullivan; P Asselman; D Buckwell; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

Review 7.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

8.  A data mining methodology for predicting early stage Parkinson's disease using non-invasive, high-dimensional gait sensor data.

Authors:  Conrad Tucker; Yixiang Han; Harriet Black Nembhard; Mechelle Lewis; Wang-Chien Lee; Nicholas W Sterling; Xuemei Huang
Journal:  IIE Trans Healthc Syst Eng       Date:  2015-11-20

Review 9.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

10.  Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Authors:  Cynthia S Palmer; Mark J C Nuijten; Jordana K Schmier; Prasun Subedi; Edward H Snyder
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.